Drugs / Mononuclear cells

Trials 5 · a red edge is where a trial was stopped

PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 21 trial
Phase 2 NCT07698080 Jul 2026 → Jul 2028 expected aplastic anemia, leukemia, lymphoma, myelodysplastic syndrome +1 Hematology department of the 920th hospital Not yet recruiting No outcome recorded
Phase not applicable4 trials
NCT05808010 Jun 2023 → Apr 2025 chronic atrophic gastritis Shandong Provincial Hospital Unknown No outcome recorded
NCT06427642 Apr 2022 → May 2024 brain hypoxia - ischemia, bronchopulmonary dysplasia, short bowel syndrome Shandong Qilu Stem Cells Engineering Co., Ltd. Unknown No outcome recorded
NCT04893629 May 2021 → Nov 2024 cardiomyopathy Damascus University Terminated No outcome recorded
NCT02721940 Feb 2012 → Jan 2015 osteonecrosis Chinese PLA General Hospital Unknown No outcome recorded
Also used as a comparator or background therapy in 3 trials
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 11 trial
Phase 1 NCT00908856 Comparator Jan 2016 → Dec 2017 stroke disorder University of California, Irvine Withdrawn No outcome recorded
Phase 22 trials
Phase 2 NCT06629324 Comparator Oct 2024 → Oct 2026 expected autism spectrum disorder Vinmec Research Institute of Stem Cell and Gene Technology Recruiting No outcome recorded
Phase 2 NCT01456819 Comparator Mar 2011 → Dec 2015 limb ischemia National University of Malaysia Unknown No outcome recorded

Evidence & citations 4 cited values

Every value below carries the sentence it was read from. 8 sources stand behind the page.

FieldValueCited text
Known as mono nuclear cells ClinicalTrials.gov intervention name — accepted as the source's own label NCT04893629
5

NCT02721940

NCT05808010

NCT07698080

NCT01456819

NCT06427642

Known as Autologous Bone Marrow Mononuclear Cell Transfusion ClinicalTrials.gov intervention name — accepted as the source's own label NCT06629324
1

NCT00908856

Modality Cell therapy Cell therapy with mononuclear cells and mesenchymal stem cells from bone marrow is promising” NCT01456819
Route Intravenous “a single intravenous transfusion approximately 2 days after bone marrow aspiration, and 4 days after stroke onset” NCT00908856